Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Liabilities (2016 - 2026)

Akebia Therapeutics has reported Total Liabilities over the past 11 years, most recently at $344.0 million for Q4 2025.

  • Quarterly Total Liabilities rose 27.46% to $344.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $344.0 million through Dec 2025, up 27.46% year-over-year, with the annual reading at $344.0 million for FY2025, 27.46% up from the prior year.
  • Total Liabilities was $344.0 million for Q4 2025 at Akebia Therapeutics, up from $322.6 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $519.2 million in Q1 2022 and troughed at $252.7 million in Q1 2024.
  • The 5-year median for Total Liabilities is $319.5 million (2025), against an average of $349.0 million.
  • Year-over-year, Total Liabilities grew 29.86% in 2021 and then tumbled 42.21% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $455.3 million in 2021, then dropped by 22.95% to $350.8 million in 2022, then decreased by 22.39% to $272.3 million in 2023, then dropped by 0.89% to $269.9 million in 2024, then rose by 27.46% to $344.0 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Total Liabilities are $344.0 million (Q4 2025), $322.6 million (Q3 2025), and $316.4 million (Q2 2025).